Glucagon-like Peptide-1 (GLP-1)[edit]

Principals funcions GLP-1

Glucagon-like peptide-1 (GLP-1) is a hormone that is secreted from the intestines in response to food intake. It plays a crucial role in the regulation of blood glucose levels and has been implicated in the pathophysiology of type 2 diabetes.

Glucagon-like Peptide-1 (GLP-1) is an incretin hormone that plays a critical role in glucose metabolism, insulin secretion, and appetite regulation. Produced in the intestinal L cells and certain neurons within the brain, GLP-1 is a key player in the enteroinsular axis, mediating the increase in insulin secretion in response to nutrient intake. This article delves into the physiological functions of GLP-1, its therapeutic applications, particularly in the treatment of type 2 diabetes mellitus and obesity, and highlights recent research in the field.

Physiological Role[edit]

GLP-1 exerts multiple actions on glucose homeostasis and gastrointestinal function:

Insulin Secretion: Enhances insulin secretion from pancreatic β-cells in a glucose-dependent manner, preventing hyperglycemic spikes post-meal.
Gastric Emptying: Slows gastric emptying, aiding in the reduction of postprandial glucose levels.
Appetite Regulation: Acts on the brain to promote satiety and reduce food intake, contributing to weight management.
Glucagon Suppression: Inhibits glucagon secretion, thereby reducing hepatic glucose production.

File:MMDB ID 62600 PDB ID 3C59 Crystal Structure Of The Ligand-Bound Glucagon-Like Peptide- 1 Receptor Extracellular Domain.png

Illustration of insulin and glucagon regulation in glucose metabolism.

Therapeutic Uses[edit]

GLP-1's role in enhancing insulin secretion and promoting satiety has led to the development of GLP-1 receptor agonists for managing type 2 diabetes and obesity:

Type 2 Diabetes Mellitus: GLP-1 receptor agonists, such as exenatide and liraglutide, improve glycemic control by enhancing insulin secretion and suppressing glucagon release.
Obesity: These agents reduce appetite and food intake, leading to significant weight loss in patients with obesity.

GLP-1 Receptor Agonists[edit]

GLP-1 receptor agonists mimic the action of endogenous GLP-1, offering several benefits:

Improved glycemic control with a low risk of hypoglycemia
Weight reduction
Potential cardiovascular benefits

Function[edit]

GLP-1 is secreted by L cells in the intestine in response to food intake. It acts on the pancreas to stimulate insulin secretion and inhibit glucagon secretion, thereby helping to regulate blood glucose levels. GLP-1 also slows gastric emptying and promotes satiety, which can help to control body weight.

Role in disease[edit]

Impaired GLP-1 secretion and action have been implicated in the pathophysiology of type 2 diabetes. GLP-1-based therapies, such as GLP-1 receptor agonists and DPP-4 inhibitors, are currently used in the treatment of this disease.

Therapeutic use[edit]

GLP-1-based therapies are used in the treatment of type 2 diabetes. These include GLP-1 receptor agonists, which mimic the action of GLP-1, and DPP-4 inhibitors, which prevent the breakdown of GLP-1. These therapies can help to improve blood glucose control and promote weight loss.